vTv Therapeutics/$VTVT
1D1W1MYTD1Y5YMAX
Capital at risk
About vTv Therapeutics
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
- Ticker
- $VTVT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 26
- Headquarters
- High Point, United States
- Website
- vtvtherapeutics.com
vTv Therapeutics Metrics
BasicAdvanced
$395M
-
-$0.42
0.29
-
Price and volume
Market cap
$395M
Beta
0.29
52-week high
$44.00
52-week low
$19.50
Average daily volume
58K
Financial strength
Current ratio
12.482
Quick ratio
12.348
Interest coverage (TTM)
-1,541.83%
Profitability
EBITDA (TTM)
-9.245
Gross margin (TTM)
22.16%
Net profit margin (TTM)
-12.91%
Operating margin (TTM)
-25.11%
Revenue per employee (TTM)
$1,420,000
Management effectiveness
Return on assets (TTM)
-10.14%
Return on equity (TTM)
-15.80%
Valuation
Price to revenue (TTM)
9.785
Price to book
5.02
Price to tangible book (TTM)
5.02
Price to free cash flow (TTM)
-21.506
Free cash flow yield (TTM)
-4.65%
Free cash flow per share (TTM)
-1.479
Growth
Revenue change (TTM)
216,600.00%
Earnings per share change (TTM)
-85.91%
3-year revenue growth (CAGR)
1,499.64%
10-year revenue growth (CAGR)
44.68%
3-year earnings per share growth (CAGR)
-64.03%
10-year earnings per share growth (CAGR)
-39.50%
What the Analysts think about vTv Therapeutics
Analyst ratings (Buy, Hold, Sell) for vTv Therapeutics stock.
Analyst projections of the future price of vTv Therapeutics stock.
Bulls say / Bears say
Phase 3 CATT1 trial enrollment is on track for completion in Q3 2026, with a cash balance of $98.1 million expected to fund operations through the anticipated topline data readout, marking a clear runway to a potential pivotal value inflection (GlobeNewswire(sec.gov)).
In February 2026, vTv amended its license agreement with Newsoara Biopharma to grant global rights to HPP737, receiving a $20 million upfront payment and unlocking up to $115 million in milestones and royalties, strengthening its non-dilutive capital resources (GlobeNewswire(sec.gov)).
The company plans to initiate a Phase 2a hybrid closed-loop trial of cadisegliatin by year-end 2026, demonstrating strategic diversification of its Type 1 diabetes program to integrate with advanced insulin delivery systems (GlobeNewswire(ir.vtvtherapeutics.com))
Cash and cash equivalents declined to $86.6 million as of June 30, 2026 from $98.9 million at year-end 2025, reflecting a high cash burn rate that may pressure liquidity if the CATT1 trial is delayed (GlobeNewswire(ir.vtvtherapeutics.com)).
Net loss attributable to shareholders widened to $13.1 million in Q2 2026 versus $6.0 million in Q2 2025, indicating escalating R&D and G&A expenses that could strain financial resources ahead of commercial revenues (GlobeNewswire(ir.vtvtherapeutics.com)).
Data summarised monthly by Lightyear AI. Last updated on 25 Aug 2026.
vTv Therapeutics Financial Performance
Revenues and expenses
vTv Therapeutics Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.